Table 3.
Risk Factor | N | Cumulative Incidence | 95% CI | P-value | |
---|---|---|---|---|---|
Age (years) | <20 | 32 | 22% | 8- 36% | <0.01 |
20-40 | 25 | 16% | 2- 30% | ||
≥40 | 63 | 46% | 33- 59% | ||
Sex | Male | 69 | 36% | 25- 48% | 0.45 |
Female | 51 | 29% | 17- 42% | ||
Malignant Disease | Yes | 96 | 39% | 28- 49% | 0.01 |
No | 24 | 13% | 0- 25% | ||
Previous aGVHD | Yes | 61 | 39% | 27- 52% | 0.32 |
No | 59 | 27% | 16- 39% | ||
Previous chronic GVHD | Yes | 44 | 43% | 28- 58% | 0.11 |
No | 76 | 28% | 17- 38% | ||
Chemo-DLI | Yes | 37 | 59% | 42- 77% | <0.01 |
No | 83 | 22% | 13- 31% | ||
Time from HCT to DLI (days) | <200 | 45 | 44% | 29- 60% | 0.01 |
≥200 | 75 | 27% | 17- 37% | ||
Donor Type | Sibling | 83 | 30% | 20- 40% | 0.29 |
URD | 37 | 41% | 24- 57% | ||
DLI Dose (CD3 /kg) | <1×107 | 27 | 19% | 4- 33% | 0.23 |
1×107-1×108 | 65 | 35% | 23- 47% | ||
≥1×108 | 28 | 43% | 24- 62% |